Aug. 31 at 2:41 PM
$NUMIF Q4 FY25: revenue C
$2.33M (+29% QoQ), gross profit C
$1.42M (+63.5% QoQ), gross margin 61.2% (up from 48.3%). Practitioner Training revenue +387.6% to C
$1.0M drove the beat; Cedar Clinical Research revenue fell 13.2% to C
$1.4M on seasonality, though trial volume actually grew (18 trials, 306 appointments vs. 15/233 prior quarter).
Quarterly net loss widened to C
$881,837. Cash is thin at C
$0.5M against a C
$2.7M working-capital deficit, and the company remains under a cease-trade order pending completion of its audit.
$NUMIF #Psychedelics #Biotech
https://prismmarketview.com/numinus-wellness-reports-29-quarterly-revenue-growth-as-practitioner-training-accelerates/